• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Betting on Fallen Angels Could Be Heavenly

If you have an appetite for risk, there are buying opportunities.
By JOHN REESE
Jan 15, 2016 | 08:00 AM EST
Stocks quotes in this article: GSK, LAZ

When the market dives, heading for cover may not be your best bet. For those with an appetite for risk, this is a buying opportunity. Of course, blindly buying a stock that has headed south is a bad idea; many such stocks were probably overpriced or have cloudy futures and may remain underwater for some time.

But judiciously choosing fallen angels now can pay off later. I choose stocks by relying on computerized strategies I created that mirror how some of Wall Street's savviest thinkers invest. One of these strategies is based on "Mr. Contrarian," David Dreman, who made his name by going against the flow. Below are a couple of stocks my Dreman-based strategy likes at this time.

But to limit risk, I chose stocks not only earning the Dreman strategy's approval, but earning hosannas from one other strategy as well. Two strategies proclaiming a stock a good buying opportunity make it worth careful consideration.

The two stocks are GlaxoSmithKline (GSK) and Lazard (LAZ). Glaxo is a global pharmaceutical giant, while Lazard is a notable investment banking house. The Dreman strategy focuses on medium to large companies, which applies to both these names. To determine if a stock is contrarian (out of favor with the market) the stock must pass at least two of the following four tests: a P/E ratio, price-to-cash flow ratio, price-to-book ratio or price-to-dividend ratio that is in the bottom 20% of the market. Glaxo's P/E and price-to-dividend ratios are in this bottom 20% cohort, while Lazard's P/E ratio and price-cash flow ratio meet these bottom-dwelling criteria. (Lazard is part of TheStreet's Growth Seeker portfolio.)

To be sure, the company must be financially strong, as the strategy wants to see a return on equity from among the top third of the 1,500 largest-cap stocks, which is 16.85%. Glaxo's ROE is 187.3%, while Lazard's is 115.9%. Both of these ROEs is very impressive. Also in the companies' favor are strong yields: 6.15% for Glaxo and 4.21% for Lazard.

In addition to the Dreman-based plan, my strategy constructed on the foundation created by James P. O'Shaughnessy strongly favors Glaxo. The company's huge market cap of $97 billion, strong cash flow per share, large number of outstanding shares, large annual sales ($34 billion) and solid dividend all add up to a strong performance, as measured by my O'Shaughnessy strategy.

Lazard gets a nod from my Peter Lynch-modeled strategy, which focuses on the P/E/G ratio (price-to-earnings relative to growth), a measure of how well a stock is priced. A P/E/G of up to 1.0 is acceptable, and below 0.5 is a very strong showing. Lazard's P/E/G is an outstanding 0.16, indicating its stock is extremely well priced.

Given today's market, both these companies have their risks. But they are also operating well and have strong financials and well-priced stocks. These are good reasons to consider investing in these companies at this time.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Reese was long GSK, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Novavax Stock Needs a Booster Shot

Bruce Kamich
Oct 4, 2023 1:37 PM EDT

Let's roll up our sleeves and check out the charts and indicators.

An Update on My Top Small-Cap Pick and What It Means for the Overall Market

James "Rev Shark" DePorre
Sep 26, 2023 11:30 AM EDT

The good news is that the corrective action is advancing and opportunities are developing.

Moderna's Chart Messages Are Frustrating the Bulls

Bruce Kamich
Sep 19, 2023 9:20 AM EDT

The technical indicators suggest that traders should wait until a bottom pattern plays out in the shares of the vaccine maker.

This Biotech Stock Pick Is Just Starting to Make Beautiful Music

Bret Jensen
Sep 15, 2023 9:00 AM EDT

Things have started to turn up for this midcap name. Look for these shares to end the year on an up note.

UnitedHealth Shares Are Not Looking All That Healthy

Bruce Kamich
Sep 14, 2023 11:05 AM EDT

Let's take the temperature of this important Dow component.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:13 PM EDT BRUCE KAMICH

    8 Trading Rules from T. T. Hoyne

    You just read the header for this missive and prob...
  • 08:42 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How Elite Traders Make Big Profits
  • 02:58 PM EDT BRUCE KAMICH

    Classic Trading Rules From Bernard Baruch

    Bernard Baruch listed the rules (below) in his aut...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login